Browsing by Author Brahmer, Julie R.

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 中
Showing results 1 to 4 of 4
TitleAuthor(s)Issue Date
 
Five-Year Outcomes with Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer with PD-L1 Tumor Proportion Score ‡ 50%
Journal:Journal of Clinical Oncology
Reck, MartinRodríguez-Abreu, DelvysRobinson, Andrew G.Hui, RinaCsöszi, TiborFülöp, AndreaGottfried, MayaPeled, NirTafreshi, AliCuffe, SineadO’Brien, MaryRao, SumanHotta, KatsuyukiLeal, Ticiana A.Riess, Jonathan W.Jensen, ErinZhao, BinPietanza, M. CatherineBrahmer, Julie R.
2021
 
Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial
Journal:The Lancet Oncology
Brahmer, Julie R.Rodríguez-Abreu, DelvysRobinson, Andrew G.Hui, RinaCsőszi, TiborFülöp, AndreaGottfried, MayaPeled, NirTafreshi, AliCuffe, SineadO'Brien, MaryRao, SumanHotta, KatsuyukiZhang, JinLubiniecki, Gregory M.Deitz, Anne C.Rangwala, ReshmaReck, Martin
2017
 
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Journal:New England Journal of Medicine
Reck, MartinRodriguez-Abreu, DelvysRobinson, Andrew G.Hui, RinaCsöszi, TiborFülöp, AndreaGottfried, MayaPeled, NirTafreshi, AliCuffe, SineadO'Brien, MaryRao, SumanHotta, KatsuyukiLeiby, Melanie A.Lubiniecki, Gregory M.Shentu, YueRangwala, ReshmaBrahmer, Julie R.
2016
 
Updated analysis of KEYNOTE-024: Pembrolizumab versus platinum-based chemotherapy for advanced non–small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater
Journal:Journal of Clinical Oncology
Reck, MartinRodríguez-Abreu, DelvysRobinson, Andrew G.Hui, RinaCsoszi, TiborFülöp, AndreaGottfried, MayaPeled, NirTafreshi, AliCuffe, SineadO’Brien, MaryRao, SumanHotta, KatsuyukiVandormael, KristelRiccio, AntonioYang, JingCatherine Pietanza, M.Brahmer, Julie R.
2019
Showing results 1 to 4 of 4